Renovorx appoints former chief medical officer of schering-plough, robert j. spiegel, md, facp, to board of directors

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (lapc), announced today that robert j. spiegel, md, has been appointed to the company's board of directors, effective april 25, 2023. dr. spiegel brings more than 40 years of biopharmaceutical experience to renovorx's board. he was involved in more than 30 successful new dr.
RNXT Ratings Summary
RNXT Quant Ranking